97-11715. Availability of Exclusive Licensing of U.S. Patent Application Concerning Liposomes Including Sterols Having Thiol Moieties and Peptides or Proteins Including CTL Epitopes and Administration Thereof

[Federal Register Volume 62, Number 87 (Tuesday, May 6, 1997)]
[Notices]
[Page 24645]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-11715]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability of Exclusive Licensing of U.S. Patent Application 
Concerning Liposomes Including Sterols Having Thiol Moieties and 
Peptides or Proteins Including CTL Epitopes and Administration Thereof

AGENCY: U.S. Army Medical Research and Materiel Command, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability for licensing of U.S. Patent Application Serial No. 08/
764,469, entitled ``Liposomes Including Sterols Having Thiol Moieties 
and Peptides or Proteins Including CTL Epitopes and Administration 
Thereof,'' filed July 2, 1996. This patent has been assigned to the 
United States Government as represented by the Secretary of the Army.

ADDRESSES: Office of the Command Judge Advocate, U.S. Army Medical 
Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 
21702-5012, Attn: MCMR-JA.

FOR FURTHER INFORMATION CONTACT:
CPT Elizabeth Arwine, Legal Advisor, [phone] or fax (301) 619-
5034.

SUPPLEMENTARY INFORMATION: This invention is a method for production of 
an unlimited number of uniquely modified liposomes which result in an 
enhanced cytotoxic T lymphocyte (CTL) response and which can be used in 
production of vaccines and reagents. Modification occurs by altering 
the liposomes to include at least one sterol having at least one thiol 
moiety and which include peptides or proteins. Examples of the method's 
utility include synthesis of peptides which may be used in construction 
of vaccines directed against viral and bacterial pathogens, composed of 
varied HIV subunits, or in which enhanced CTL activity is desired.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 97-11715 Filed 5-5-97; 8:45 am]
BILLING CODE 3710-08-M